NIKA PHARMACEUTICALS, INC (NIKA): M&A transaction — Nika Pharmaceuticals provides Form 10 info, discloses ownership and auditor change as former shell

NIKA PHARMACEUTICALS, INC

Change of control completed Apr 1, 2022: Dimitar Savov acquired 87% of common stock for $140,000.
As of Aug 31, 2023, Savov holds 38.04% common stock and 100% preferred stock, controlling 100% voting power.
Company ceased to be a shell as of Apr 11, 2022; business focus on TNG production and dietary supplements.
Auditor changed: dismissed Pinnacle Accountancy Group on Aug 18, 2022; engaged BF Borgers CPA PC on Oct 24, 2022.
Common stock not traded on any exchange; approximately 64 holders of record as of Sept 14, 2023.

item 1.01 item 2.01 item 9.01 item 3.02 item 3.03 item 5.01 item 5.06

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

NIKA PHARMACEUTICALS, INC underwent a change of control involving Dimitar Slavchev Savov for $140,000 (closed 2022-04-01).

Action: change of control
Counterparty: Dimitar Slavchev Savov
Consideration: $140,000
Closing: 2022-04-01

Exact text from the filing

As a result of the purchase by Dimitar Slavchev Savov of a total of 11,489,000 (87%) shares of common stock of the Company from the Company’s former President and CEO, Mr. Phil E. Ray and certain other shareholders for $140,000, a change in control of the Company occurred as of April 1, 2022.

View on SEC.gov

Browse all m&a transactions →

NIKA PHARMACEUTICALS, INC filing history →

Source: SEC EDGAR

accession 0001826466-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.